Clarity Pharmaceuticals Ltd. (AU:CU6) has released an update.
Clarity Pharmaceuticals Ltd. has announced a Clinical Supply Agreement with NorthStar Medical Radioisotopes for the production of Cu-67 SAR-bisPSMA, intended for late-stage cancer therapy trials. This partnership aims to streamline the manufacturing process, ensuring a stable supply of the therapeutic isotope and radiopharmaceutical product from a single U.S. location. The agreement is set to support the company’s ongoing prostate cancer trials and bolster its position in the growing oncology sector.
For further insights into AU:CU6 stock, check out TipRanks’ Stock Analysis page.
